



## **Serogrouping as a valid but incomplete method to diagnose diarrheagenic *Escherichia coli***

Maria Pardos de La Gandara, Sophie Lefevre, François-Xavier Weill

### **► To cite this version:**

Maria Pardos de La Gandara, Sophie Lefevre, François-Xavier Weill. Serogrouping as a valid but incomplete method to diagnose diarrheagenic *Escherichia coli*. Romanian archives of microbiology and immunology, 2018, 77 (4), pp.315-316. <hal-02864016>

**HAL Id: hal-02864016**

**<https://hal.science/hal-02864016v1>**

Submitted on 10 Jun 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

---

## LETTER TO THE EDITOR

---

### SEROGROUPING AS A VALID BUT INCOMPLETE METHOD TO DIAGNOSE DIARRHEAGENIC *ESCHERICHIA COLI*

---

**Maria Pardos de la Gandara, Sophie Lefevre, François-Xavier Weill**

*French National Reference Centre for E. coli, Shigella and Salmonella  
Enteric Bacterial Pathogens Unit, Institut Pasteur, Paris, France*

In the recent article by Codruța-Romanița Usein *et al.* published in the latest issue of the *Romanian Archives of Microbiology and Immunology* the authors alert about the insufficiency of commercial O antisera for a correct diagnosis of diarrheagenic *Escherichia coli* [1]. In their study, the authors show that additional procedures including amplification of virulence genes are essential for a correct identification of enteropathogenic *E. coli* (EPEC) and Shiga toxin-producing *E. coli* (STEC)/Enterohemorrhagic *E. coli* (EHEC).

Bacterial identification and characterization techniques have evolved fast since the introduction of molecular methods during the 1990s to the use of genomics in recent years. But economic and technical restraints prevent laboratories all over the world from joining the genetics/genomics race in a routine basis. Commercial O antisera remain then the best resource for detection of EPEC and EHEC.

A limitation of commercial kits for serogrouping is that they only target major groups of EPEC and EHEC, defined a long time ago [2]. But the diarrheagenic *E. coli* populations circulating in each country might evolve along time. That has been the case of O80 and O26, which are displacing O157 as the predominant serogroup of EHEC in France and other countries in Europe in recent years [3, 4]. O80:H2 EHEC was described as a hybrid pathotype, with both intestinal (*stx*, *eae*, *ehxA*) and extraintestinal virulence factors, and a unusual multidrug resistant profile (to aminopenicillins, aminoglycosides, nalidixic acid, cotrimoxazole, tetracycline, and

phenicols). Severe extraintestinal infections caused by O80 were recently described in Europe [5, 6, 7]. The EHEC O26:H11 international outbreak in 2016 was a multi-strain event, with strains carrying different virulence genes – some strains carrying *stx1a*, *stx2a*, *eae*, while *stx2a* was missing in others. The outbreak, related to a dairy producer in Italy, affected patients in Romania and Italy, and it supposed the largest EHEC-associated HUS outbreak in Italy to date [8, 9, 10].

Also, epidemics can eventually be caused by infrequent serogroups, like O104, which caused an international outbreak in 2011, centred in Germany, with more than 3800 cases. This O104:H4 strain was also hybrid, characterized by the combination of EHEC typical virulence genes (*stx1*, *stx2*, *eae*, and *ehx*) and atypical ones as the *aggR* gene, which is the defining factor for enteroaggregative *E. coli* (EAEC) strains [11]. In order to detect outbreaks and epidemics like these, antisera will be insufficient to identify the new clones, for which virulence genes will have to be searched [12].

Eventually, strains belonging to the typical serogroups of EPEC and EHEC might not carry the expected virulence genes [1, 13, 14], so pathogenic clones can be overestimated and medical measures including antimicrobial therapy might be over-prescribed.

EPEC and enterotoxigenic *E. coli* (ETEC) are endemic in developing countries, while in developed countries major outbreaks are caused by EHEC. Molecular characterisation of *E. coli* strains targeting the adequate virulence

genes is needed in order to prevent under estimation of those clones [15].

Therefore, efforts must be held to search for virulence factors in parallel to a correct identification of serogroups, to properly identify circulating and emerging diarrheagenic *E. coli* populations, thus establish treatment and public health measures.

## REFERENCES

1. Usein CR, Ciontea AS, Militaru M, Condei M, & Cristea D. Using O Serogrouping Alone To Ascertain The Diarrheagenic *Escherichia coli* Should Be Discouraged. *Romanian Archives of Microbiology and Immunology*, 2018;77(2):148–152. Retrieved from [http://www.roami.ro/files/2\\_2018/148-152\\_Art\\_Usein\(web\).pdf](http://www.roami.ro/files/2_2018/148-152_Art_Usein(web).pdf).
2. Trabulsi LR, Keller R, & Tardelli Gomes, TA. Typical and atypical enteropathogenic *Escherichia coli*. *Emerging Infectious Diseases*. 2002;8(5): 508–513. <https://doi.org/10.3201/eid0805.010385>.
3. Cointe A, Birgy A, Mariani-Kurkdjian P, Liguori S, Courroux C, Blanco J, et al. Emerging Multidrug-Resistant Hybrid Pathotype Shiga Toxin-Producing *Escherichia coli* O80 and Related Strains of Clonal Complex 165, Europe. *Emerging Infectious Diseases*. 2018;24(12). <https://doi.org/10.3201/eid2412.180272>.
4. Usein CR, Ciontea AS, Militaru CM, Condei M, Dinu S, Oprea M, et al. Molecular characterisation of human shiga toxin producing *Escherichia coli* O26 strains: Results of an outbreak investigation, Romania, February to August 2016. *Eurosurveillance*, 2017;22(47):1–8. <https://doi.org/10.2807/1560-7917.ES.2017.22.47.17-00148>.
5. Mariani-Kurkdjian P, Lemaitre C, Bidet P, Perez D, Boggini L, Kwon T, et al. Haemolytic-uraemic syndrome with bacteraemia caused by a new hybrid *Escherichia coli* pathotype. *New Microbes and New Infections*. 2014;2(4): 127–131. <https://doi.org/10.1002/nmi2.49>.
6. Soysal N, Mariani-Kurkdjian P, Smail Y, Liguori S, Gouali M, Loukiadis E, et al. Enterohemorrhagic *Escherichia coli* hybrid pathotype O80:H2 as a new therapeutic challenge. *Emerging Infectious Diseases*, 2016;22(9):1604–1612. <https://doi.org/10.3201/eid2209.160304>.
7. Wijnsma KL, Schijvens AM, Rossen JWA, Kooistra-Smid AMD, Mirjam Schreuder MF, van de Kar NCAJ. Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing *E. coli* O80:H2. *Pediatric Nephrology*, 2017;32(7):1263–1268. <https://doi.org/10.1007/s00467-017-3642-3>.
8. European Centre for Disease Prevention and Control/European Food Safety Authority. Johansson K, Niskanen T, Mardh O, Takkinen J, Jansa J, Peron E, et al. Multi-country outbreak of STEC infection associated with HUS – 5 April 2016. Stockholm:ECDC;2016
9. Germinario C, Caprioli A, Giordano M, Chironna M, Gallone MS, Tafuri S, et al. Community-wide outbreak of haemolytic uraemic syndrome associated with Shiga toxin 2-producing *Escherichia coli* O26: H11 in southern Italy, summer 2013. *Eurosurveillance*, 2016;21(38):1–9. <https://doi.org/10.2807/1560-7917.ES.2016.21.38.30343>.
10. Peron E, Zaharia A, Zota LC, Severi E, Mårdh O, Usein, C, et al. Early findings in outbreak of haemolytic uraemic syndrome among young children caused by Shiga toxin-producing *Escherichia coli*, Romania, January to February 2016. *Eurosurveillance*, 2016;21(11):30170. <https://doi.org/10.2807/1560-7917.ES.2016.21.11.30170>.
11. Frank C, Werberm Dirk, Cramer JP, Askar M, Mirko Faber M.D, Matthias an der Heiden PhD, et al. Epidemic Profile of Shiga-Toxin-Producing Outbreak in Germany. *New England Journal of Medicine*, 2011;365(19), 1771–1780. <https://doi.org/10.1056/NEJMoa1106483>.
12. Rosin P, Niskanen T, Palm D, Struelens M & Takkinen J. Laboratory preparedness for detection and monitoring of Shiga toxin 2-producing *Escherichia coli* o104:H4 in Europe and response to the 2011 outbreak. *Eurosurveillance*, 2013;18(25):1–9. <https://doi.org/10.2807/1560-7917.ES2013.18.25.20508>.
13. Keen JE, Wittum TE, Dunn JR, Bono JL & Durso LM. O157 in Agricultural Fair Livestock, United States. *Emerging Infectious Diseases (CDC)*, 2006;12(5). <https://doi.org/10.3201/eid1205.050984>.
14. Schmidt H, Scheef J, Huppertz HI, Frosch M, & Karch H. *Escherichia coli* O157:H7 and O157:H- strains that do not produce shiga toxin: Phenotypic and genetic characterization of isolates associated with diarrhea and hemolytic-uremic syndrome. *Journal of Clinical Microbiology*, 1999;37(11): 3491–3496.
15. Rojas-Lopez M, Monterio, R, Pizza M, Desvaux M, & Rosini R. Intestinal pathogenic *Escherichia coli*: Insights for vaccine development. *Frontiers in Microbiology*, 9(MAR), 2018;1–17. <https://doi.org/10.3389/fmicb.2018.00440>.